gene therapy

News

Close Up Of Senior Man Suffering With Parkinsons Diesease

Axovant pushes on with Parkinson's gene therapy, despite inv...

Axovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from a small cohort of patients from a phase 2 trial.

News

EMA starts rapid review of Bluebird’s gene therapy for rare ...

Bluebird bio could be just a few months away from approval of its gene therapy for rare disease cerebral adrenoleukodystrophy (CALD) in the EU, after the EMA started an accelerated review.<

Events

Partner Content

2nd Digital Exosome Based Therapeutic Development Summit

Advancing the Success of Exosome Therapeutics

News

Novartis' bid to expand use of SMA gene therapy delayed afte...

Analysts have said the FDA’s request for a new trial will delay Novartis’ intrathecal formulation of its spinal muscular atrophy (SMA) gene therapy in older patients until 2023, potentially

Views & Analysis

Preparing for an influx of cell and gene therapy approvals

Cell and gene therapies offer some of the most groundbreaking advancements in patient care the pharma industry has ever seen.

News

Biogen plans trial of Spinraza in patients not responding to...

Biogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded properly to Novartis' gene therapy Zolgensma, combining the two ultra-expensiv

Axovant pushes on with Parkinson's gene therapy, despite inv...

EMA starts rapid review of Bluebird’s gene therapy for rare ...

2nd Digital Exosome Based Therapeutic Development Summit

Novartis' bid to expand use of SMA gene therapy delayed afte...

Preparing for an influx of cell and gene therapy approvals

Biogen plans trial of Spinraza in patients not responding to...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

gene therapy

Editor's Picks